CAMP4 Therapeutics Corporation (NASDAQ:CAMP) Given Average Recommendation of “Moderate Buy” by Brokerages

Shares of CAMP4 Therapeutics Corporation (NASDAQ:CAMPGet Free Report) have been given a consensus recommendation of “Moderate Buy” by the seven research firms that are currently covering the company, Marketbeat reports. One analyst has rated the stock with a sell rating, one has issued a hold rating and five have given a buy rating to the company. The average twelve-month target price among analysts that have issued ratings on the stock in the last year is $8.60.

Several equities research analysts have recently weighed in on CAMP shares. Cantor Fitzgerald reaffirmed an “overweight” rating on shares of CAMP4 Therapeutics in a research report on Friday, March 6th. Rodman & Renshaw started coverage on shares of CAMP4 Therapeutics in a research report on Tuesday, April 14th. They issued a “buy” rating and a $7.00 price target for the company. Leerink Partners upped their price target on shares of CAMP4 Therapeutics from $8.00 to $9.00 and gave the stock an “outperform” rating in a research report on Thursday, April 2nd. Finally, Weiss Ratings cut shares of CAMP4 Therapeutics from a “sell (d-)” rating to a “sell (e+)” rating in a research report on Thursday, May 21st.

View Our Latest Research Report on CAMP4 Therapeutics

Institutional Investors Weigh In On CAMP4 Therapeutics

A number of hedge funds and other institutional investors have recently bought and sold shares of the company. Bank of America Corp DE lifted its position in CAMP4 Therapeutics by 141,700.0% during the first quarter. Bank of America Corp DE now owns 31,196 shares of the Wireless communications provider’s stock valued at $138,000 after acquiring an additional 31,174 shares during the last quarter. SummitTX Capital L.P. purchased a new stake in CAMP4 Therapeutics during the first quarter valued at approximately $1,497,000. Janus Henderson Group PLC lifted its position in CAMP4 Therapeutics by 35.9% during the fourth quarter. Janus Henderson Group PLC now owns 6,307,636 shares of the Wireless communications provider’s stock valued at $38,807,000 after acquiring an additional 1,666,666 shares during the last quarter. EcoR1 Capital LLC acquired a new position in CAMP4 Therapeutics during the 4th quarter valued at approximately $1,992,000. Finally, Balyasny Asset Management L.P. purchased a new position in shares of CAMP4 Therapeutics in the fourth quarter worth $14,938,000.

CAMP4 Therapeutics Price Performance

Shares of CAMP stock opened at $4.21 on Thursday. The company has a market capitalization of $218.63 million, a P/E ratio of -1.78 and a beta of 0.04. The company’s 50-day simple moving average is $4.49 and its two-hundred day simple moving average is $4.67. CAMP4 Therapeutics has a one year low of $1.30 and a one year high of $7.75.

CAMP4 Therapeutics (NASDAQ:CAMPGet Free Report) last announced its quarterly earnings results on Thursday, May 7th. The Wireless communications provider reported ($0.32) earnings per share for the quarter, missing the consensus estimate of ($0.21) by ($0.11). CAMP4 Therapeutics had a negative return on equity of 194.74% and a negative net margin of 2,193.72%.The business had revenue of $1.29 million during the quarter. On average, research analysts expect that CAMP4 Therapeutics will post -0.8 EPS for the current fiscal year.

About CAMP4 Therapeutics

(Get Free Report)

CalAmp Corp., a connected intelligence company, provides leverages a data-driven solutions ecosystem to people and organizations in the United States, Europe, the Middle East, Africa, Latin America, the Asia-Pacific, and internationally. The company operates in two segments, Software & Subscription Services and Telematics Products. It provides CalAmp Telematics Cloud platform, such as cloud-based application enablement and telematics service platforms that facilitate integration of its own applications, as well as those of third parties, through open application programming interfaces; and software as a service application, as well as provides tracking and monitoring services within fleet management, supply chain integrity, and international vehicle location.

Featured Stories

Analyst Recommendations for CAMP4 Therapeutics (NASDAQ:CAMP)

Receive News & Ratings for CAMP4 Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for CAMP4 Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.